Relmada Therapeutics, Inc. (RLMD)

NASDAQ: RLMD · IEX Real-Time Price · USD
2.26
+0.02 (0.89%)
At close: Mar 31, 2023, 4:00 PM
2.17
-0.09 (-3.98%)
After-hours: Mar 31, 2023, 7:50 PM EDT
0.89%
Market Cap 68.02M
Revenue (ttm) n/a
Net Income (ttm) -157.04M
Shares Out 30.10M
EPS (ttm) -5.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 339,092
Open 2.25
Previous Close 2.24
Day's Range 2.12 - 2.32
52-Week Range 1.81 - 38.68
Beta 0.16
Analysts Buy
Price Target 11.60 (+413.27%)
Earnings Date May 4, 2023

About RLMD

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 10
Stock Exchange NASDAQ
Ticker Symbol RLMD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for RLMD stock is "Buy." The 12-month stock price forecast is $11.6, which is an increase of 413.27% from the latest price.

Price Target
$11.6
(413.27% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

CORAL GABLES, Fla. , March 23, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provide...

1 week ago - PRNewsWire

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 23, 2023

CORAL GABLES, Fla. , March 17, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announc...

2 weeks ago - PRNewsWire

Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors

CORAL GABLES, Fla. , Jan. 12, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announce...

2 months ago - PRNewsWire

Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer

CORAL GABLES, Fla. , Jan. 9, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced...

2 months ago - PRNewsWire

Relmada Therapeutics shares decline 40% on Thursday

Shares of Relmada Therapeutics Inc. RLMD, -0.95% tumbled about 40% in premarket trading on Thursday, the day after the company said its experimental depression drug did not meet the primary endpoint i...

4 months ago - Market Watch

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder

Company to Host Conference Call Today, December 7, 2022, at 5:00 PM ET CORAL GABLES, Fla. , Dec. 7, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company a...

4 months ago - PRNewsWire

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

CORAL GABLES, Fla. , Nov. 10, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided...

5 months ago - PRNewsWire

Relmada Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 10, 2022

CORAL GABLES, Fla. , Nov. 8, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced...

5 months ago - PRNewsWire

Steven Cohen's Firm Boosts Stakes in Relmada and Immunic

Steven Cohen (Trades, Portfolio), chairman and CEO of Point72 Asset Management, disclosed in regulatory filings that his firm established a position in Progress Acquistion Corp. ( PGRWU , Financial) a...

Other symbols: IMUX
5 months ago - GuruFocus

Relmada (RLMD) Lead Candidate Fails Late-Stage Depression Study

Relmada's (RLMD) phase III study, evaluating REL-1017 in major depressive disorder, fails to achieve statistical significance. Shares plunge 80% following the news.

6 months ago - Zacks Investment Research

Why Is Relmada (RLMD) Stock Down 78% Today?

Source: Shutterstock Relmada Therapeutics (NASDAQ: RLMD) stock is plummeting on Thursday as investors react to results from a Phase 3 clinical trial. Unfortunately for RLMD stock, its RELIANCE III st...

6 months ago - InvestorPlace

Relmada's stock tumbles 80% after its depressive disorder drug failed a late-stage study

Shares of Relmada Therapeutics Inc. RLMD, -0.97% fell 80.0% in premarket trading on Thursday after the biotech said its experimental treatment for major depressive disorder as a monotherapy did not me...

6 months ago - Market Watch

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

RELIANCE I and II Adjunctive MDD Trials Continue to Advance CORAL GABLES, Fla. , Oct. 13, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing ...

6 months ago - PRNewsWire

Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder

CORAL GABLES, Fla. , Sept. 20, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announc...

6 months ago - PRNewsWire

Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

CORAL GABLES, Fla. , Aug. 11, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD) ("Relmada," the "Company," "we," "us, "our"), a late-stage biotechnology company addressing diseases of the...

8 months ago - PRNewsWire

Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

CORAL GABLES, Fla. , Aug. 9, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced...

8 months ago - PRNewsWire

Relmada Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022

CORAL GABLES, Fla. , Aug. 5, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced...

8 months ago - PRNewsWire

Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial

Company Continues Commercial Preparations in Advance of Phase III Clinical Trial Readouts for REL-1017 in Major Depressive Disorder Expected in 2022 CORAL GABLES, Fla. , July 21, 2022 /PRNewswire/ -- ...

9 months ago - PRNewsWire

Relmada Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

CORAL GABLES, Fla. , June 7, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced...

10 months ago - PRNewsWire

Relmada Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference

CORAL GABLES, Fla. , June 2, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced...

10 months ago - PRNewsWire

Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2022 Annual Meeting

CORAL GABLES, Fla., May 25, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today ...

11 months ago - PRNewsWire

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

CORAL GABLES, Fla. , May 5, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a...

11 months ago - PRNewsWire

Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology

CORAL GABLES, Fla. , April 29, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced tod...

1 year ago - PRNewsWire

Relmada Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022

CORAL GABLES, Fla. , April 28, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announc...

1 year ago - PRNewsWire

Relmada Therapeutics to Present Data at the Ketamine & Related Compounds International Hybrid Conference 2022

CORAL GABLES, Fla. , April 4, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced toda...

1 year ago - PRNewsWire